en · de · es · pt
thymosin-alpha-1-notes.peptides6155.com › Topic › Molecular Background And Immune Action — Research Overview

Molecular Background And Immune Action — Research Overview

By Editorial Desk · published 2025-09-27 · last reviewed 2025-11-08 · Topic

This is a working overview of Thymosin alpha 1, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2025-11-08 and is reviewed periodically as new material appears.

Molecular Background and Immune Action

Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.

Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.

Background, Structure, and Mechanism

Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.

Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.

Thymosin-alpha-1 at a glance

PropertyValueNotes
Molecular mass≈3,108 DaSynthetic 28-residue peptide
Amino acid count28N-terminal serine carries an acetyl group
AppearanceWhite to off-white powderLyophilized solid
Water solubilityFreely solubleDissolves in aqueous buffer
Common synonymsThymalfasin; Tα1Thymalfasin is the international nonproprietary name

Background and Molecular Identity

Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.

Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.

The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.

Related pages on this site

Background and Mechanism of Action

Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.

Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.

Supporting material

== Precursor == Pepsin is expressed as a zymogen called pepsinogen, whose primary structure has an additional 44 amino acids compared to the active enzyme. In the stomach, gastric chief cells release pepsinogen. This zymogen is activated by hydrochloric acid (HCl), which is released from parietal cells in the stomach lining. The hormone gastrin and the vagus nerve trigger the release of both pepsinogen and HCl from the stomach lining when food is ingested. Hydrochloric acid creates an acidic environment, which allows pepsinogen to unfold and cleave itself in an autocatalytic fashion, thereby generating pepsin (the active form). Pepsin cleaves the 44 amino acids from pepsinogen to create more pepsin. Pepsinogens are mainly grouped in 5 different groups based on their primary structure: pepsinogen A (also called pepsinogen I), pepsinogen B, progastricsin (also called pepsinogen II and pepsinogen C), prochymosin (also called prorennin) and pepsinogen F (also called pregnancy-associated glycoprotein).

=== Tuberculosis === The primary use of isoniazid is as first-line treatment for latent and active infection of Mycobacterium tuberculosis, the causative agent of tuberculosis (TB). In persons with isoniazid-resistant Mycobacterium tuberculosis infection, drug regimens based on isoniazid have a high rate of failure. In the United States, the indications for isoniazid use approved by the U.S. Food and Drug Administration (FDA) include:.

=== Cardiovascular function === Relaxin has been shown to relax vascular smooth muscle cells and increase nitric oxide production in rat endothelial cells, thus playing a role in regulation of cardiovascular function by dilating systemic resistance arteries. Relaxin increases the rate and force of cardiac contraction in rat models and has been found to promote maturation of cardiomyocytes in mice. Several animal studies have found relaxin to have a cardioprotective function against ischaemia and reperfusion injury, by reducing cellular damage, via anti-apoptotic and anti-inflammatory effects. Relaxin has been shown to reduce cardiac fibrosis in animal models by inhibiting cardiac fibroblasts secreting collagen and stimulating matrix metalloproteinase. In the European rabbit (Oryctolagus cuniculus), relaxin is associated with squamous differentiation and is expressed in tracheobronchial epithelial cells as opposed to being involved with reproduction.

Sixty-four countries initially joined; it was ratified and came into force in the US in 1967. The Convention on Psychotropic Substances of 1971 added synthetic, prescription and hallucinogenic drugs. The United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988 addressed international drug trafficking and "criminalized the entire drug market chain, from cultivation/production to shipment, sale, and possession." In 1968, President Lyndon B. Johnson (1963–69) decided that the government needed to make an effort to curtail the social unrest that blanketed the country at the time. He focused on illegal drug use, an approach that was in line with expert opinion on the subject at the time. In the 1960s, it was believed that at least half of the crime in the US was drug-related, and this estimate grew as high as 90% in the next decade. He created the Reorganization Plan of 1968 which merged the Bureau of Narcotics and the Bureau of Drug Abuse Control to form the Bureau of Narcotics and Dangerous Drugs within the Department of Justice.

Sources: en.wikipedia.org

Notes from published material

Normally, when an item is quenched, the final temperature is ambient. The only reason for this is that most heat treaters do not have cooling equipment. There is nothing metallurgically significant about ambient temperature. The cryogenic process continues this action from ambient temperature down to −320 °F (140 °R; 78 K; −196 °C). In most instances the cryogenic cycle is followed by a heat tempering procedure. As all alloys do not have the same chemical constituents, the tempering procedure varies according to the material's chemical composition, thermal history and/or a tool's particular service application. The entire process takes 3–4 days.

=== OpenStack === NASA developed a cloud compute platform to give additional computer and storage resources for its engineers, called Nebula. In July 2010, the Nebula code was released as open source and NASA partnered with Rackspace, to form the OpenStack project. OpenStack is used in the cloud-based products from many companies in the cloud market.

== Modern reactions == To this day, Jameson's involvement in the Jameson Raid remains something of an enigma, being somewhat out-of-character with his prior history, the rest of his life and successful later political career. In 2002, The Van Riebeeck Society published Sir Graham Bower's Secret History of the Jameson Raid and the South African Crisis, 1895–1902 (edited by Deryck Schreuder and Jeffrey Butler, Van Riebeeck Society, Cape Town, Second Series No. 33), adding to growing historical evidence that the imprisonment and judgement upon the Raiders at the time of their trial was unjust, in view of what has appeared, in later historical analysis, to have been the calculated political manoeuvres by Joseph Chamberlain and his staff to hide his own involvement and knowledge of the Raid. In a 2004 review of Sir Graham Bower's account, Alan Cousins commented that "A number of major themes and concerns emerge" from Bower's history, "perhaps the most poignant being Bower’s accounts of his being made a scapegoat in the aftermath of the raid: 'since a scapegoat was wanted I was willing to serve my country in that capacity'." Cousins writes of Bower that:

prophase The first stage of cell division in both mitosis and meiosis, occurring after interphase and before prometaphase, during which the DNA of the chromosomes is condensed into chromatin, the nucleolus disintegrates, centrosomes move to opposite ends of the cell, and the mitotic spindle forms.

== Biography == Sakel was born to a Jewish family on June 6, 1900, in Nadvirna (Nadwórna), in the former Austria-Hungary Empire (now Ukraine), which was part of Poland between the world wars. Sakel studied Medicine at the University of Vienna from 1919 to 1925, specializing in neurology and neuropsychiatry. From 1927 until 1933 Sakel worked in hospitals in Berlin. In 1933 he became a researcher for the University of Vienna's Neuropsychiatric Clinic. In 1936, after receiving an invitation from Frederick Parsons, a commissioner of mental hygiene, he chose to emigrate from Austria to the United States of America. In the USA, he became an attending physician and researcher at the Harlem Valley State Hospital. Dr. Sakel was the developer of insulin shock therapy from 1927 while a young doctor in Vienna, starting to practice it in 1933. It would become used widely for individuals with schizophrenia and other mental patients. He noted that insulin-induced coma and convulsions, due to the low level of glucose attained in the blood (hypoglycemic crisis), had a short-term appearance of changing the mental state of drug addicts and psychotics, sometimes dramatically. He reported that as many as 88% of his patients improved with insulin shock therapy, but most other people reported more mixed results and it was shown eventually that patient selection had been biased and that it didn't really have any specific benefits and had many risks, adverse effects and fatalities. However, his method was used for many years in mental institutions worldwide.

Sources: en.wikipedia.org

Further detail

Only some of the Ruthenian szlachta of the Chernigov region, who had their origins in the Moscow state, saved their lands from division among Cossacks and became part of the Cossack szlachta. After this, the Ruthenian szlachta refrained from plans to have a Moscow Tsar as king of the Commonwealth, its own Michał Korybut Wiśniowiecki later becoming king. The last, ultimately unsuccessful, attempt to rebuild the Polish–Cossack alliance and create a Polish–Lithuanian–Ruthenian Commonwealth was the 1658 Treaty of Hadiach. The treaty was approved by the Polish king and the Sejm, and by some of the Cossack starshyna, including hetman Ivan Vyhovsky. The treaty failed, however, because the starshyna were divided on the issue, and it had even less support among rank-and-file Cossacks.

== Stress response == Small changes in cellular oxidant status can be sensed by specific proteins which regulate a set of genes encoding antioxidant enzymes. Such a global response induces an adaptive metabolism including ROS elimination, the bypass of injured pathways, reparation of oxidative damages and maintenance of reducing power. Peroxide and superoxide are the two major active oxygen species. It is found that the peroxide and superoxide stress responses are distinct in bacteria. The exposure of microorganisms to low sublethal concentrations of oxidants leads to the acquisition of cellular resistance to a subsequent lethal oxidative stress.

=== Degradation and autolysis === Proteases, being themselves proteins, are cleaved by other protease molecules, sometimes of the same variety. This acts as a method of regulation of protease activity. Some proteases are less active after autolysis (e.g. TEV protease) whilst others are more active (e.g. trypsinogen).

== List of women chemists == The following list is split into the centuries when the majority of the scientist's work was performed. The scientist's listed may be born and perform work outside of the century they are listed under.

Sources: en.wikipedia.org

Frequently asked questions

What is thymosin alpha 1 made of?

It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.

Is thymosin alpha 1 a hormone?

It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.

Where is thymosin alpha 1 approved?

Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.

What is thymosin alpha-1 derived from?

It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.

Network